These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28455847)

  • 21. Variations in health-related quality of life in Japanese men who underwent iodine-125 permanent brachytherapy for localized prostate cancer.
    Tanaka N; Fujimoto K; Asakawa I; Hirayama A; Yoneda T; Yoshida K; Hirao Y; Hasegawa M; Konishi N
    Brachytherapy; 2010; 9(4):300-6. PubMed ID: 20708440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite.
    Kakehi Y; Takegami M; Suzukamo Y; Namiki S; Arai Y; Kamoto T; Ogawa O; Fukuhara S
    J Urol; 2007 May; 177(5):1856-61. PubMed ID: 17437836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of high dose rate brachytherapy in combination with external beam radiotherapy on men's health-related quality of life and sexual function over a 2 year time span.
    Conaglen HM; de Jong D; Hartopeanu C; Conaglen JV; Tyrie LK
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):197-204. PubMed ID: 23183305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Orgasm after curietherapy with permanent iodine-125 radioimplants for localized prostate cancer].
    Delaunay B; Delannes M; Salloum A; Delavierre D; Wagner F; Jonca F; Thoulouzan M; Plante P; Bachaud JM; Soulie M; Huyghe E
    Prog Urol; 2011 Dec; 21(13):932-9. PubMed ID: 22118358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients.
    Yorozu A; Kuroiwa N; Takahashi A; Toya K; Saito S; Nishiyama T; Yagi Y; Tanaka T; Shiraishi Y; Ohashi T
    Brachytherapy; 2015; 14(2):111-7. PubMed ID: 25127123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer.
    Stock RG; Stone NN; Iannuzzi C
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):267-72. PubMed ID: 8635932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study.
    Nakano M; Yorozu A; Saito S; Sugawara A; Maruo S; Kojima S; Kikuchi T; Fukushima M; Dokiya T; Yamanaka H
    Radiat Oncol; 2015 Nov; 10():228. PubMed ID: 26577301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
    BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
    Teishima J; Iwamoto H; Miyamoto K; Shoji K; Masumoto H; Inoue S; Kobayashi K; Kajiwara M; Matsubara A
    Int J Urol; 2012 Dec; 19(12):1083-9. PubMed ID: 22852805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.
    Ishiyama H; Satoh T; Kitano M; Tsumura H; Kotani S; Okusa H; Uemae M; Baba S; Hayakawa K
    Jpn J Clin Oncol; 2008 Jul; 38(7):469-73. PubMed ID: 18577509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
    Wust P; von Borczyskowski DW; Henkel T; Rosner C; Graf R; Tilly W; Budach V; Felix R; Kahmann F
    Radiother Oncol; 2004 Oct; 73(1):39-48. PubMed ID: 15465144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study.
    Ohashi T; Yorozu A; Saito S; Tanaka N; Katayama N; Kojima S; Maruo S; Kikuchi T; Dokiya T; Fukushima M; Yamanaka H
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):141-9. PubMed ID: 26279031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
    Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
    BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy.
    Solan AN; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1468-74. PubMed ID: 18922652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy.
    Valicenti RK; Bissonette EA; Chen C; Theodorescu D
    J Urol; 2002 Dec; 168(6):2499-504; discussion 2504. PubMed ID: 12441949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer.
    Pinkawa M; Fischedick K; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Urology; 2006 Jul; 68(1):104-9. PubMed ID: 16806434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference.
    Miller DC; Wei JT; Dunn RL; Montie JE; Pimentel H; Sandler HM; McLaughlin PW; Sanda MG
    Urology; 2006 Jul; 68(1):166-71. PubMed ID: 16844457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive factors of rectal toxicity after permanent iodine-125 seed implantation: Prospective cohort study in 2339 patients.
    Katayama N; Yorozu A; Maruo S; Kojima S; Ohashi T; Tanaka N; Kikuchi T; Higashide S; Saito S; Dokiya T; Fukushima M; Yamanaka H
    Brachytherapy; 2016; 15(6):736-745. PubMed ID: 27720311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
    Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
    Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Quadrella: a novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy.
    Tétreault-Laflamme A; Zilli T; Meissner A; Larrivée S; Sylvestre MP; Delouya G; Taussky D
    Radiother Oncol; 2014 Apr; 111(1):110-3. PubMed ID: 24560751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.